NDAINTRAVENOUSSOLUTION
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Clinical Trials (5)
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Started Apr 2025
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Started Jan 2016
20 enrolled
Pancreatic AdenocarcinomaResectable Pancreatic Carcinoma
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Started Sep 2015
32 enrolled
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and Ureter+6 more
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Started May 2015
10 enrolled
LymphomaSolid Neoplasm
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Started Mar 2015
0Duct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic Cancer+2 more
Loss of Exclusivity
LOE Date
Jul 1, 2033
89 months away
Patent Expiry
Jul 1, 2033
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9241948 | Jul 1, 2033 | Product | — |